The aim of this article was to review the current role of PET/computed tomography (CT) in soft tissue sarcomas with respect to staging, restaging, and prognostic value. Fluorine-18-fluorodeoxyglucose PET, for instance, can be very useful in differentiating recurrent disease from scar tissue during follow-up. Other indications of PET-CT are still evolving, especially in the light of new molecular drugs. Different aspects of PET/CT imaging in soft tissue sarcomas are overviewed including organ-specific merits, limitations, and potential pitfalls. Finally, methodological considerations on PET/MRI are also briefly discussed.